CL2014003567A1 - Composición que comprende iduronato-2-sulfatasa (i2s) recombinante; formulación que la comprende; método de purificación de i2s recombinante; composición farmacéutica; y uso para tratar síndrome de hunter. - Google Patents

Composición que comprende iduronato-2-sulfatasa (i2s) recombinante; formulación que la comprende; método de purificación de i2s recombinante; composición farmacéutica; y uso para tratar síndrome de hunter.

Info

Publication number
CL2014003567A1
CL2014003567A1 CL2014003567A CL2014003567A CL2014003567A1 CL 2014003567 A1 CL2014003567 A1 CL 2014003567A1 CL 2014003567 A CL2014003567 A CL 2014003567A CL 2014003567 A CL2014003567 A CL 2014003567A CL 2014003567 A1 CL2014003567 A1 CL 2014003567A1
Authority
CL
Chile
Prior art keywords
recombinant
composition
sulfatase
formulation
purification method
Prior art date
Application number
CL2014003567A
Other languages
English (en)
Spanish (es)
Inventor
Dave Nichols
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003567(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of CL2014003567A1 publication Critical patent/CL2014003567A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CL2014003567A 2012-06-29 2014-12-29 Composición que comprende iduronato-2-sulfatasa (i2s) recombinante; formulación que la comprende; método de purificación de i2s recombinante; composición farmacéutica; y uso para tratar síndrome de hunter. CL2014003567A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
CL2014003567A1 true CL2014003567A1 (es) 2015-04-24

Family

ID=49778401

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003567A CL2014003567A1 (es) 2012-06-29 2014-12-29 Composición que comprende iduronato-2-sulfatasa (i2s) recombinante; formulación que la comprende; método de purificación de i2s recombinante; composición farmacéutica; y uso para tratar síndrome de hunter.

Country Status (39)

Country Link
US (7) US9051556B2 (OSRAM)
EP (2) EP3441398A1 (OSRAM)
JP (4) JP6171007B2 (OSRAM)
KR (5) KR101380740B1 (OSRAM)
CN (3) CN107596357A (OSRAM)
AR (1) AR091647A1 (OSRAM)
AU (3) AU2013282395C1 (OSRAM)
BR (1) BR112014032567B1 (OSRAM)
CA (2) CA3008945A1 (OSRAM)
CL (1) CL2014003567A1 (OSRAM)
CO (1) CO7240396A2 (OSRAM)
CR (1) CR20140588A (OSRAM)
CY (1) CY1121519T1 (OSRAM)
DK (1) DK2867245T3 (OSRAM)
DO (1) DOP2014000294A (OSRAM)
EA (2) EA034549B1 (OSRAM)
ES (1) ES2689468T3 (OSRAM)
GT (1) GT201400303A (OSRAM)
HK (3) HK1209431A1 (OSRAM)
HR (1) HRP20181897T1 (OSRAM)
HU (1) HUE040769T2 (OSRAM)
IL (4) IL236315A (OSRAM)
LT (1) LT2867245T (OSRAM)
MX (3) MX393364B (OSRAM)
MY (3) MY157087A (OSRAM)
NZ (3) NZ743910A (OSRAM)
PE (1) PE20150720A1 (OSRAM)
PH (3) PH12014502871B1 (OSRAM)
PL (1) PL2867245T3 (OSRAM)
PT (1) PT2867245T (OSRAM)
RS (1) RS58005B1 (OSRAM)
SG (2) SG11201408761VA (OSRAM)
SI (1) SI2867245T1 (OSRAM)
SM (1) SMT201800612T1 (OSRAM)
TR (1) TR201815811T4 (OSRAM)
TW (2) TWI587869B (OSRAM)
UA (2) UA129561C2 (OSRAM)
WO (1) WO2014005014A2 (OSRAM)
ZA (2) ZA201409397B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2182980A4 (en) 2007-07-27 2012-04-18 Armagen Technologies Inc METHOD AND COMPOSITIONS FOR INCREASED ALPHA IDURONIDASE ACTIVITY IN THE CNS
HRP20190690T1 (hr) 2009-10-09 2019-06-28 Armagen, Inc. Postupci i pripravci za povećanje aktiviteta iduronat-2-sulfataze u centralnom nervnom sustavu
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
MX389073B (es) 2016-08-25 2025-03-20 Japan Chem Res Método para producir una proteína de fusión de anticuerpo.
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
WO2019070577A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EP3898689A1 (en) * 2018-12-20 2021-10-27 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
MX2021008983A (es) * 2019-01-30 2021-09-08 Amgen Inc Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
KR20220111693A (ko) 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법
CA3173820A1 (en) * 2020-10-23 2022-04-28 Alexion Pharmaceuticals, Inc. Method of controlling total sialic acid content (tsac) during manufacturing of alkaline phosphatase
KR20230145120A (ko) 2021-02-12 2023-10-17 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩타이드 및 이의 사용 방법

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
WO1995024920A1 (en) 1994-03-16 1995-09-21 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP2218775B1 (en) 1996-08-30 2015-01-28 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
EP1171615B1 (en) 1999-04-26 2006-12-13 Genentech, Inc. Cell culture process for glycoproteins
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
AU7099200A (en) 1999-09-03 2001-04-10 Human Genome Sciences, Inc. 52 human secreted proteins
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
CA2400034A1 (en) 2000-02-17 2001-08-23 Incyte Genomics, Inc. Human kinases
CA2400638A1 (en) 2000-03-17 2001-09-27 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
CA2511520A1 (en) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
DK2325302T3 (en) 2003-02-11 2016-03-14 Shire Human Genetic Therapies Cells expressing a sulfatase and a C-formylglycine-generating enzyme and methods and uses thereof
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
ES2370417T3 (es) 2005-06-03 2011-12-15 Ares Trading S.A. Producción de una proteína de unión a il-18 recombinante.
CA2645739A1 (en) 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
BRPI0906948B1 (pt) * 2008-01-18 2023-05-16 Biomarin Pharmaceutical, Inc Composições compreendendo uma enzima nacetilgalactosamina-6- sulfatase (galns) recombinante humana e uso das mesmas para tratar mucopolissacaridose tipo iva, síndrome de morquio a, ou deficiência múltipla de sulfatase
HRP20190690T1 (hr) 2009-10-09 2019-06-28 Armagen, Inc. Postupci i pripravci za povećanje aktiviteta iduronat-2-sulfataze u centralnom nervnom sustavu
JPWO2011108451A1 (ja) * 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
MX2013000324A (es) * 2010-06-25 2013-02-01 Shire Human Genetic Therapies Tratamiento del sindrome de sanfilippo tipo b.
PL2593131T3 (pl) 2010-06-25 2020-01-31 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
EP2623118A4 (en) * 2010-09-28 2014-05-07 Kyoritsu Seiyaku Corp MUCOSAL ADJUVANT COMPOSITION
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
WO2012105954A1 (en) 2011-01-31 2012-08-09 Hewlett-Packard Development Company, L. P. A diffuser with a dynamically tunable scattering angle
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Also Published As

Publication number Publication date
AR091647A1 (es) 2015-02-18
PH12015502408A1 (en) 2018-03-26
CA3008945A1 (en) 2014-01-03
ZA201803289B (en) 2021-04-28
US20140004096A1 (en) 2014-01-02
AU2018200230B2 (en) 2020-01-02
TW201410868A (zh) 2014-03-16
JP2018121645A (ja) 2018-08-09
TR201815811T4 (tr) 2018-11-21
AU2013282395A1 (en) 2015-01-29
JP2015523072A (ja) 2015-08-13
JP2016119911A (ja) 2016-07-07
EP2867245A2 (en) 2015-05-06
BR112014032567A2 (pt) 2017-08-01
EP2867245B1 (en) 2018-09-12
HK1209767A1 (en) 2016-04-08
TW201703794A (zh) 2017-02-01
IL236315A0 (en) 2015-02-26
KR20190064542A (ko) 2019-06-10
CA2877517A1 (en) 2014-01-03
CR20140588A (es) 2015-04-06
CN104583225A (zh) 2015-04-29
SI2867245T1 (sl) 2018-12-31
MX366906B (es) 2019-07-30
HUE040769T2 (hu) 2019-03-28
PH12015502408B1 (en) 2020-02-14
JP2020105209A (ja) 2020-07-09
PH12014502871A1 (en) 2015-02-23
AU2013282395B2 (en) 2015-12-03
EA201492177A1 (ru) 2015-06-30
DOP2014000294A (es) 2015-03-15
US12359178B2 (en) 2025-07-15
IL236315A (en) 2016-11-30
CN107596357A (zh) 2018-01-19
US20170073652A1 (en) 2017-03-16
ES2689468T3 (es) 2018-11-14
KR20220002227A (ko) 2022-01-06
US20190359958A1 (en) 2019-11-28
DK2867245T3 (en) 2018-11-26
PL2867245T3 (pl) 2019-02-28
US11530393B2 (en) 2022-12-20
GT201400303A (es) 2017-08-31
EA202090044A1 (ru) 2020-07-31
PE20150720A1 (es) 2015-05-16
WO2014005014A2 (en) 2014-01-03
CA2877517C (en) 2018-07-31
JP7594365B2 (ja) 2024-12-04
IL287057A (en) 2021-12-01
HK1249026A1 (zh) 2018-10-26
HRP20181897T1 (hr) 2019-01-11
NZ733366A (en) 2019-12-20
IL261264B (en) 2021-10-31
US20150313972A1 (en) 2015-11-05
UA129561C2 (uk) 2025-06-04
MX393364B (es) 2025-03-19
MX336715B (es) 2016-01-28
US20210317426A1 (en) 2021-10-14
SG10201703489VA (en) 2017-05-30
US20240401010A1 (en) 2024-12-05
KR20140002451A (ko) 2014-01-08
US10344270B2 (en) 2019-07-09
CN107596358A (zh) 2018-01-19
CY1121519T1 (el) 2020-05-29
US20240043817A1 (en) 2024-02-08
PH12014502871B1 (en) 2015-02-23
LT2867245T (lt) 2018-11-12
MY180287A (en) 2020-11-27
AU2016200469A1 (en) 2016-02-18
KR101380740B1 (ko) 2014-04-11
RS58005B1 (sr) 2019-02-28
SG11201408761VA (en) 2015-01-29
JP6505629B2 (ja) 2019-04-24
IL248727A0 (en) 2017-01-31
WO2014005014A3 (en) 2014-02-27
EA034549B1 (ru) 2020-02-19
JP6171007B2 (ja) 2017-07-26
IL261264A (en) 2018-10-31
ZA201409397B (en) 2019-10-30
MX2015000190A (es) 2015-04-08
BR112014032567B1 (pt) 2022-09-13
TWI553120B (zh) 2016-10-11
PH12020500027A1 (en) 2021-03-15
AU2016200469B2 (en) 2017-10-12
HK1209431A1 (en) 2016-04-01
HK1249027A1 (zh) 2018-10-26
CO7240396A2 (es) 2015-04-17
US9051556B2 (en) 2015-06-09
NZ703093A (en) 2017-08-25
KR20200143339A (ko) 2020-12-23
US9492511B2 (en) 2016-11-15
TWI587869B (zh) 2017-06-21
PT2867245T (pt) 2018-11-26
KR20140004603A (ko) 2014-01-13
MY157087A (en) 2016-04-19
MY192068A (en) 2022-07-25
UA121959C2 (uk) 2020-08-25
NZ743910A (en) 2019-12-20
MX2019008914A (es) 2019-09-26
SMT201800612T1 (it) 2019-01-11
EP2867245A4 (en) 2016-03-09
AU2018200230A1 (en) 2018-02-01
AU2013282395C1 (en) 2016-03-24
EP3441398A1 (en) 2019-02-13

Similar Documents

Publication Publication Date Title
CL2014003567A1 (es) Composición que comprende iduronato-2-sulfatasa (i2s) recombinante; formulación que la comprende; método de purificación de i2s recombinante; composición farmacéutica; y uso para tratar síndrome de hunter.
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
CL2013001107A1 (es) Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas.
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CL2016001166A1 (es) Silicato de zirconio microporoso para el tratamiento de la hipercalemia
CL2014003357A1 (es) Composición sinérgica para la protección de cultivos agrícolas y su uso
DK2841097T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom
DK3329909T3 (da) Fenfluramin til anvendelse i behandling af dravet syndrom
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
BR112014031262A2 (pt) composições biocatalisadoras inovadoras e processos para uso.
CL2014000948A1 (es) Profarmaco de adrenomedulina basado en polietilenglicol; procedimiento de preparacion; composicion farmaceutica que lo comprende; y su uso para tratar y/o prevenir trastornos cardiovasculares, edematosos y/o inflamatorios.
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
EP2705181A4 (en) PHARMACEUTICAL COMBINATION COMPOSITIONS AND ITS USE
DK2861223T3 (da) Sammensætninger og metoder til transmukosal absorption
EP3031322A4 (en) Composition comprising harmful arthropod-attracting substance formed from plant-derived components and analogs thereof
HRP20190573T1 (hr) Piranokromenil fenol derivat, i farmaceutska kompozicija za liječenje metaboličkog sindroma ili inflamatorne bolesti
CL2015000049A1 (es) Método y composición para secuestrar arsénico.
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
BR112014028280A2 (pt) composições farmacêuticas tópicas compreendendo terbinafina e ureia
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
BR112015027026A8 (pt) composição para uso na redução da formação de casca e na promoção da cicatrização
BR112015012149A2 (pt) método para a remoção de uma ou mais substâncias químicas de um material de tabaco, material de tabaco, artigo para fumar e uso de um líquido iônico para remover proteínas e/ou polifenóis
BR112015008798A2 (pt) método para o tratamento de plantas e uso